Comparative efficacy and safety of faricimab, aflibercept, conbercept, and ranibizumab for neovascular age-related macular degeneration: A systematic review and network meta-analysis
OftalmologiaSobre o estudo
- Desenho
- Revisão sistemática
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- European journal of pharmacology
- Publicado em
- 25 nov 2025
- Citações
- 2
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Comparative efficacy and safety of faricimab, aflibercept, conbercept, and ranibizumab for neovascular age-related macular degeneration: A systematic review and network meta-analysis
Shanduo Cen, Shixin Liu, Miaomiao Zhao, Lei Tang
Descritores MeSH
- Ranibizumab
- Macular Degeneration
- Recombinant Fusion Proteins
- Choroidal Neovascularization
- Angiogenesis Inhibitors
- Receptors, Vascular Endothelial Growth Factor
- Humans
- Treatment Outcome
- Antibodies, Bispecific
- Visual Acuity
Veja também
Estudos relacionados
- Effect of Anti-VEGF Therapy on the Disease Progression of Neovascular Age-Related Macular Degeneration: A Systematic Review and Model-Based Meta-Analysis
- Comparative efficacy of photodynamic therapy (PDT), ranibizumab, aflibercept monotherapy, and combination therapies for polypoidal choroidal vasculopathy: a network meta-analysis of randomized controlled trials
- Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration
- Aflibercept versus ranibizumab for diabetic macular edema: A meta-analysis